Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age

NCT ID: NCT00329849

Last Updated: 2018-10-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1500 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-05-31
• Study Completion Date: 2007-03-31

Brief Summary

Safety and immunogenicity of meningococcal ACWY conjugate versus polysaccharide vaccine in children 2 to 10 years of age

Conditions

Meningococcal Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

MenACWY-CRM

Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)

Group Type: EXPERIMENTAL

Meningococcal ACWY-CRM conjugate vaccine

Intervention Type: BIOLOGICAL

MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.

MenACWY-PS

Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS)

Group Type: ACTIVE_COMPARATOR

Meningococcal ACWY-PS polysaccharide vaccine

Intervention Type: BIOLOGICAL

MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.

Interventions

Meningococcal ACWY-CRM conjugate vaccine

MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.

Intervention Type: BIOLOGICAL

Meningococcal ACWY-PS polysaccharide vaccine

MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Healthy children 2 to 10 years of age inclusive whose parents or legal guardians gave written informed consent at the time of enrollment;
• Available for all visits and telephone calls (parents or legal guardians) scheduled for the study;
• Good health as determined by the clinical judgment of the investigator.

Exclusion Criteria

Individuals not eligible to be enrolled into the study were those:

• whose parent or legal guardian was unwilling or unable to give written informed consent to participate in the study;
• whose parent or legal guardian were perceived as unreliable or unavailable for the duration of the study period;
• who had a previous or suspected disease caused by N meningitidis;
• who had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis infection within 60 days prior to enrollment;
• who had previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) (licensed or investigational);
• who had received any investigational agents or vaccines within 90 days prior to enrollment or who expected to receive an investigational agent or vaccine prior to the completion of the study;
• who had received any licensed vaccines within one month prior to enrollment or for whom receipt of a licensed vaccine was anticipated within one month after vaccination (Exception: influenza vaccine could be administered up to 15 days prior to study vaccination and no less than 15 days after study vaccination);
• who had received a live viral vaccine within 60 days prior to enrollment;
• who had experienced, within the 7 days prior to enrollment, significant acute or chronic infection (for example requiring systemic antibiotic treatment or antiviral therapy) or had experienced fever (defined as axillary temperature ≥38°C) within 3 days prior to enrollment;
• who had any serious acute, chronic or progressive disease (e.g., any history of neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS), or blood dyscrasias, with signs of cardiac or renal failure or severe malnutrition). (Exception: subjects with mild asthma were eligible for enrollment; subjects with moderate or severe asthma requiring routine use of inhaled or systemic corticosteroids were not eligible for enrollment);
• who had epilepsy or any progressive neurological disease;
• who had a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine component;
• who had a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):
• receipt of immunosuppressive therapy within 30 days prior to enrollment (any systemic corticosteroid administered for more than 5 days, or in a daily dose >1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy);
• receipt of immunostimulants;
• receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study;
• common childhood exanthematous diseases (varicella, mumps, measles, rubella) occurring 6 weeks prior to vaccination;
• who were known to have a bleeding diathesis or any condition that could be associated with a prolonged bleeding time;
• who had Down syndrome or other known cytogenic disorders;
• whose families were planning to leave the area of the study site before the end of the study period;
• who had any condition that, in the opinion of the investigator, could interfere with the evaluation of the study objectives.

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 10 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Novartis Vaccines

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Vaccines & Diagnostics

Role: STUDY_CHAIR

Novartis Vaccines & Diagnostics

Locations

FUNCEI, French 3085

Buenos Aires, , Argentina

Centro di Desarrollo de Proyectos Avanzados (CEDEPAP) Roma 1464

Córdoba, , Argentina

Hospital de Pediatria "Sor Maria Ludovica", Calle 14 N1631,(1900)

La Plata, , Argentina

Countries

Argentina

References

Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine. 2010 Jan 8;28(3):657-63. doi: 10.1016/j.vaccine.2009.10.104. Epub 2009 Nov 4.

Reference Type: RESULT

PMID: 19895922 (View on PubMed)

Other Identifiers

V59P10

Identifier Type: -

Identifier Source: org_study_id